Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of OPC-41061 in congestive heart failure with edema
jRCT2080220454Phase 3
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in heart failure (HF) and edema secondary to heart failure, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Primary safety of OPC-41061 treatment beyond 7 days and Effect of dose escalation to 30 mg.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)edema secondary to heart failure
Beyond the preview
Go deeper on jRCT2080220454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220454.